This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OCX OncoCyte (OCX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About OncoCyte Stock (NASDAQ:OCX) 30 days 90 days 365 days Advanced Chart Get OncoCyte alerts:Sign Up Key Stats Today's Range N/A50-Day Range$2.60▼$3.4452-Week Range N/AVolume100,514 shsAverage Volume58,260 shsMarket Capitalization$90.80 millionP/E RatioN/ADividend YieldN/APrice Target$6.06Consensus RatingModerate Buy Company Overview OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Read More OncoCyte Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreOCX MarketRank™: OncoCyte scored higher than 23% of companies evaluated by MarketBeat, and ranked 850th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingOncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOncoCyte has received no research coverage in the past 90 days.Read more about OncoCyte's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OncoCyte are expected to grow in the coming year, from ($2.57) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OncoCyte is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OncoCyte is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OCX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOncoCyte does not currently pay a dividend.Dividend GrowthOncoCyte does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for OCX. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for OCX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OncoCyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.05% of the stock of OncoCyte is held by insiders.Percentage Held by Institutions55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OncoCyte's insider trading history. Receive OCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCX Stock News HeadlinesOncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to NashvilleJune 17, 2025 | globenewswire.comOncocyte Corp. Adjusts Pricing for GraftAssureCore™ Assay to $2,753, Enhancing Market Opportunities and Reimbursement PotentialMay 21, 2025 | nasdaq.comWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.September 1 at 2:00 AM | Stansberry Research (Ad)Oncocyte Corporation: Medicare Boosts Reimbursement for Oncocyte's Flagship TechnologyMay 20, 2025 | finanznachrichten.deMedicare Boosts Reimbursement for Oncocyte’s Flagship TechnologyMay 19, 2025 | finance.yahoo.comMedicare Boosts Reimbursement for Oncocyte's Flagship TechnologyMay 19, 2025 | globenewswire.comOncocyte Corporation: Oncocyte Reports Q1 2025 Results and Business ProgressMay 13, 2025 | finanznachrichten.deOncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiativeMay 13, 2025 | msn.comSee More Headlines OCX Stock Analysis - Frequently Asked Questions How were OncoCyte's earnings last quarter? OncoCyte Corporation (NASDAQ:OCX) posted its quarterly earnings results on Monday, May, 12th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The business had revenue of $2.14 million for the quarter, compared to analyst estimates of $0.13 million. OncoCyte had a negative trailing twelve-month return on equity of 215.59% and a negative net margin of 1,516.06%. Read the conference call transcript. When did OncoCyte's stock split? Shares of OncoCyte reverse split before market open on Tuesday, July 25th 2023.The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are OncoCyte's major shareholders? Top institutional shareholders of OncoCyte include Defender Capital LLC. (0.12%). Insiders that own company stock include Broadwood Partners, LP, Pura Vida Investments, Llc, Andrea S James, Andrew Arno, Alfred D Kingsley and Josh Riggs. View institutional ownership trends. What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that OncoCyte investors own include Alibaba Group (BABA), Meta Platforms (META), Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY) and Ford Motor (F). Company Calendar Last Earnings5/12/2025Today9/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OCX CIK1642380 Weboncocyte.com Phone(949) 409-7600Fax510-521-3389Employees120Year FoundedN/APrice Target and Rating Average Price Target for OncoCyte$6.06 High Price Target$8.00 Low Price Target$4.00 Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($3.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$60.66 million Net Margins-1,516.06% Pretax Margin-1,514.57% Return on Equity-215.59% Return on Assets-27.23% Debt Debt-to-Equity Ratio0.20 Current Ratio3.74 Quick Ratio3.70 Sales & Book Value Annual Sales$3.84 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.70) per share Price / BookN/AMiscellaneous Outstanding Shares28,599,000Free Float28,013,000Market Cap$90.80 million OptionableNo Data Beta0.97 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:OCX) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.